Precision Medicine to Plan Better Treatment

Every cancer is associated with a unique combination of genomic changes. Furthermore, different cells within a tumor may harbor different genomic abnormalities. Comprehensive genomic profiling canidentify such changes in cell signaling pathways by detecting prognostic and predictive biomarkers. This information can then be used to facilitate treatment decisions. This process is known as precision medicine.

Why ACT Genomics?

Humane Process

Avoid multiple biopsies and time cost of single-gene test, few specimens required for various fusion gene detection at once.

Ideal Treatment

Find proper targeted options.

Smart Budgeting

Evaluate options before treatment according to genomic information, to ensure success rate and avoid waste of medical budget.

Why Can Cancer Change During Treatment?

Cancer can change over time. As cancer grows or responds to treatment, the genetic characteristics of tumor cells may also change. This means that genomic information obtained earlier in the treatment journey may not always reflect the tumor at a later stage.

When the disease progresses, returns, or no longer responds to treatment as expected, your doctor may need updated genomic information to better understand what has changed and evaluate the next treatment options.

How Can a Liquid Biopsy Help?

Tumor tissue is an important source of genomic information, but obtaining another tissue biopsy may not always be possible or appropriate. Liquid biopsy provides another way to assess tumor-related genomic alterations using blood or pleural effusion.

ACTLiquid™ Lite analyzes cancer-related genomic alterations and provides treatment-related information that can help your doctor evaluate treatment options. Because only a liquid specimen is required, the test may also be considered when tumor tissue is limited or unavailable.

When Might ACTLiquid™ Lite Be Considered?

Your doctor may consider obtaining updated genomic information when:

• Tumor tissue is limited or unavailable
• Systemic or targeted treatment options are being evaluated
• Disease progression or recurrence is suspected
• Drug resistance is suspected and the next treatment strategy needs to be evaluated

Genomic testing is one part of the overall clinical assessment. Your doctor will interpret the results together with yourmedical history, imaging, pathology and other clinical findings.

‍